Opinion|Videos|May 23, 2025
The Future of Chronic Hand Eczema Treatment
Author(s)Raj Chovatiya, MD, PhD
An expert discusses how new treatments for chronic hand eczema (CHE) are emerging, particularly topical delgocitinib cream, a pan-Janus kinase (JAK) inhibitor that shows promise for treating multiple etiologies of the condition without the limitations of traditional topical steroids.
Advertisement
Video content above is prompted by the following:
Future Directions of CHE Treatment
Key Themes:
- Emerging therapies: Topical delgocitinib cream, a pan-JAK inhibitor, shows promise specifically for CHE.
- Other investigational options: Topical ruxolitinib, dupilumab, and tralokinumab have shown efficacy in certain CHE populations.
- Clinical approach: Avoiding treatment delays while pursuing diagnostic workup, with consideration for targeted therapies across multiple etiologies.
Notable Insights:
Dr Chovatiya emphasized that "having a cream that can help patients across etiologies and not delay their actual treatment represents a huge potential win for us in dermatology," suggesting a paradigm shift in CHE management.
Advertisement
Related to this article
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Advertisement
Advertisement
Trending on HCPLive
1
New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity
2
Remibrutinib Receives FDA Approval for Symptomatic Dermographism
3
RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year
4
Top Reason for Leaving HAE Attacks Untreated, Survey Finds
5